- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
February 1st, 2005
"We have demonstrated the first diagnostic test for the potential Alzheimer's biomarker known as an ADDL," said Chad Mirkin, director of Northwestern's Institute for Nanotechnology. "This protein is only 5 nm wide and present in cerebrospinal fluid at very low concentration, making it difficult to detect. Our bio-barcode-amplification technology, which is a million times more sensitive than any other diagnostic technology, can accurately identify ADDLs even in CSF."
The bio-barcode-amplification technique uses 30 nm-diameter gold nanoparticles and magnetic microparticles.
|Related News Press|
Healthcare Nanotechnology (Nanomedicine) Market Size To 2020 June 5th, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015
Engineering the world’s smallest nanocrystal July 2nd, 2015
Producing spin-entangled electrons July 2nd, 2015